Summary
The effect of graded closes of clorgyline, a preferential inhibitor of MAO A, and of deprenil, a preferential inhibitor of MAO B, on the activities of serotonin-deaminating MAO (MAO A) of dopamine-deaminating MAO, and of phenethylamine-deaminating MAO, (MAO B), in rat corpus striatum were compared with the effects of the drugs on striatal levels of homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC).
The dose-response curves for the two last-mentioned dopamine metabolites closely follow those for MAO A and dopamine-deaminating activity, whether clorgyline or deprenil was used as MAO inhibitor.
In addition, the effect of these drugs on dopamine levels and on the accumulation of 3H-dopamine + 3H-methoxytyramine formed from 3H-DOPA in rat whole brain was analysed. In contrast to the marked increases caused by clorgyline, the effects of deprenil were negligible. In reserpinized rats, clorgyline potentiated the effect of l-DOPA on motor activity; deprenil did not.
These results suggest that the deamination of dopamine in vivo is almost entirely effected by MAO A.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahlenius, S., Engel, I.: Behavioural and biochemical effects of l-DOPA after inhibition of dopamine-β-hydroxylase in reserpine pretreated rats. Naunyn-Schmiedebergs Arch. Pharmak. 270, 349–360 (1971)
Andén, N. E., Roos, B. E., Werdinius, B.: On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method. Life Sci. 2, 448–458 (1963)
Atack, C. V., Magnusson, T.: Individual elution of noradrenaline (together with adrenaline), dopamine, 5-hydroxytryptamine and histamine from a single, strong cation exchange column, by means of mineral acid-organic solvent mixtures. J. Pharm. Pharmacol. 22, 625–627 (1970)
Collins, G. G. S., Sandler, M., Williams, E. D., Youdim, M. B. H.: Multiple forms of human brain mitochondrial monoamine oxidase. Nature (Lond.) 225, 817–820 (1970)
Corrodi, H., Fuxe, K.: The effect of catecholamine precursors and monoamine oxidase inhibition on the amine levels of central catecholamine neurons after reserpine treatment or tyrosine hydroxylase inhibition. Life Sci. 6, 1345–1350 (1967)
Goridis, C., Neff, N. H.: Evidence for a specific monoamine oxidase associated with sympathetic nerves. Neuropharmacology 10, 557–564 (1971)
Graeff, F. G.: The role of dopamine in motor excitation of mice induced by brain catecholamine releasers. J. Pharm. Pharmacol. 18, 627–628 (1966)
Grahame-Smith, D. G., Green, A. R.: The role of brain dopamine in the hyperactivity syndrome produced in rats after administration of l-tryptophan and a monoamine oxidase inhibitor. Proceed. Brit. Pharm. Soc. 2nd–4th Jan. 442P–443P (1974)
Hall, D. W. R., Logan, B. W., Parsons, G. H.: Further studies on the inhibition of monoamine oxidase by M+B 9302 (clorgyline). 1. Substrate specificities in various mammalian species. Biochem. Pharmacol. 18, 1447–1454 (1969)
Johnston, J. P.: Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17, 1285–1297 (1968)
Kim, H. C., D'Iorio, A.: Possible isoenzymes of monoamine oxidase in rat tissues. Canad. J. Biochem. 46, 295–297 (1968)
Kroon, M. C., Veldstra, H.: Multiple forms of rat brain mitochondrial monoamine oxidase. Subcellular localization. FEBS Letters 24, 173–176 (1972)
McCauley, R., Racker, E.: Separation of two monoamine oxidases from bovine brain. Fed. Proc. 32, 797 (1973)
Murphy, G. F., Robinson, D., Sharman, D. F.: The effect of tropolone on the formation of 3,4-dihydroxyphenylacetic acid in the brain of the mouse. Brit. J. Pharmacol. 36, 107–115 (1969)
Neff, N. H., Goridis, C.: Neuronal monoamine oxidase: specific enzyme types and their rates of formation. Advac. Biochem. Psychopharmacol. 5, 307–323 (1972)
Neff, N. H., Yang, H. Y. T.: Monoamine oxidase. II. Evaluation of the physiological role of type A and B enzyme of brain. Fed. Proc. 32, 797 (1973)
Sharman, D. F.: Methods of determination of catecholamines and their metabolites. In: Methods of neurochemistry, R. Fried, ed., p. 111. New York: Dekker 1971
Waldmeier, P., de Herdt, P., Maître, L.: Simultaneous automated estimation of noradrenaline and dopamine in brain tissue. Clin. Chem. 20, 81–83 (1974)
Waldmeier, P., Maître, L.: Lack of significance of MAO-B for in vivo deamination of dopamine. Naunyn-Schmiedeberg's Arch. Pharmacol. 287, R2 (1975)
Wurtman, R. J., Axelrod, J.: A sensitive and specific assay for the estimation of monoamine oxidase. Biochem. Pharmacol. 12, 1439–1440 (1963)
Yang, H. Y. T., Neff, N. H.: β-Phenethylamine: A specific substrate for type B monoamine oxidase of brain. J. Pharmacol. exp. Ther. 187, 365–371 (1973)
Yang, H. Y. T., Neff, N. H.: The monoamine oxidases of brain: Selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J. Pharmacol. exp. Ther. 189, 733–740 (1974)
Youdim, M. B. H.: Multiple forms of monoamine oxidase and their properties. Advanc. Biochem. Psychopharmacol. 5, 67–77 (1972a)
Youdim, M. B. H.: Multiple forms of mitochondrial monoamine oxidase. Brit. med. Bull. 29, 120–122 (1972b)
Youdim, M. B. H., Holzbauer, M., Woods, F. H.: Physicochemical properties, development, and regulation of central and peripheral monoamine oxidase activity. Neuropsychopharmacology of monoamines and regulation enzymes. E. Usdin, ed., pp. 11–28. New York: Raven Press 1974
Youdim, M. B. H., Sandler, M.: Isoenzymes of soluble monoamine oxidase from human placental and rat liver mitochondria. Biochem. J. 105, 43p (1967)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Waldmeier, P.C., Delini-Stula, A. & Maître, L. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 292, 9–14 (1976). https://doi.org/10.1007/BF00506483
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00506483